IOVA stock is on fire in Thursday’s session after Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced positive results for its LN 145, an advanced cervical cancer drug.
California-based biotechnology company, Iovance Biotherapeutics, has been one of the most interesting and innovative companies in the industry over the past year and finally, its stock is on a tear on the NASDAQ. This morning, Iovance Biotherapeutics revealed that one of its flagship drugs, known as LN 145, has returned with a clinical update and the results of the update have been welcomed by investors.
Iovance Produces Impressive Data...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.